EyePoint Pharmaceuticals Inc. buy Royal Bank of Canada
Start price
17.06.25
/
50%
€8.18
Target price
17.06.26
€24.24
Performance (%)
90.69%
Price
23.12.25
€15.32
Summary
This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada for EyePoint Pharmaceuticals Inc. has seen massive gains of 90.69%. This prediction currently runs until 17.06.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| EyePoint Pharmaceuticals Inc. | 8.269% | 8.269% |
| iShares Core DAX® | 0.650% | 3.212% |
| iShares Nasdaq 100 | 1.650% | 0.322% |
| iShares Nikkei 225® | 1.232% | 1.549% |
| iShares S&P 500 | 1.413% | 0.282% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.59
06.11.25
06.11.25
€33.89
06.11.26
06.11.26
62.58%
23.12.25
23.12.25
